Standard BioTools Inc.
LAB
NASDAQ·Healthcare·Medical - Specialties·Mkt cap $268.3M
$0.69
▲ +1.72%
P/E
3.12
Mkt Cap
$268.3M
52-Wk Range
$0.63–$1.72
52-Week Range
$0.63 - $1.72
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 49.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary multi-omic platforms enabling simultaneous protein and gene analysis with minimal signal interference
- Established partnerships with leading institutions including Caltech, Harvard University, and Caliper Life Sciences
- Comprehensive ecosystem of instruments, consumables, and software creating high customer switching costs
- Spatial biology capabilities that preserve tissue context while enabling high-dimensional molecular profiling
Bear Case
1 risk
- Average volatility.
Growth
Profitability at risk
Rising demand for precision medicine and personalized therapeutics driving adoption of advanced bioanalytical tools
Value
Deep value opportunity - significant discount to Medical Devices peers
Momentum
Weak
-14.7% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying LAB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 5, 2026
Reported EPS of -$0.07 vs -$0.01 consensus (-449.0% surprise). Revenue of $20.1M vs $20.8M expected (-3.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-449.0%
Revenue trend · last 8Q
—
+66%
-10%
-3%
-57%
-93%
-48%
-8%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$45.0M
$46.7M
$40.8M
$21.8M
$19.6M
$3.2M
$21.1M
$20.1M
Margins · last 8Q
Gross
52.4%
Operating
-126.3%
Profit
-133.1%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How LAB stacks vs Medical - Specialties
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related